Plasma S100β is a predictor for pathology and cognitive decline in Alzheimer’s disease
This study highlights plasma S100β as a promising non-invasive biomarker for early detection and progression monitoring of Alzheimer’s disease. Given its strong association with cognitive decline and AD pathology, S100β could serve as a valuable diagnostic tool, addressing the urgent need for accessible biomarkers to guide early interventions and treatment strategies.